Category: Research

Interview with CytImmune CEO Saba Malak

published date
June 17th, 2021 by

Saba Malak photo
CytImmune CEO Saba Malak

I first encountered Saba Malak when I was a summer consultant at Boston Consulting Group and he was a new MBA. We stayed in touch and when I became chairman of Advanced Practice Strategies a few years later, Saba joined the board as lead investor.

Since then, Saba has invested in various healthcare and biotech companies in the public and private markets. I never thought of Saba as an operating executive –and apparently neither did he– but a couple of years ago he became so enamored with a company he’d invested in that he decided to take the plunge and become CEO.

That company, CytImmune is establishing a global leadership role in the field of cancer nanomedicine. It is a platform company with products of its own in development. The potential is huge, and in this episode of the HealthBiz podcast Saba explains the technology and why he is confident it will ultimately help patients. The company has a Phase II development collaboration with the National Cancer Institute, and is scaling up its manufacturing to be ready.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

What’s next for healthcare as Dems take the Senate?

published date
January 6th, 2021 by

It’s a momentous week in Georgia, Washington and these United States. In this special episode of the HealthBiz podcast, Bloomberg Intelligence Analyst, Brian Rye and I discuss the health policy implications of the likely 50+1 Democratic Senate majority. Listen in as we discuss drug pricing, Medicare Advantage, and the public option.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle Podcasts and  many more services. Please consider rating the podcast on Apple Podcasts. Doing so helps the podcast reach more listeners.

Check out the rough (AI generated) transcript.


By healthcare business consultant David E. Williams, president of Health Business Group.

ICER founder Dr. Steve Pearson explains COVID-19 remdesivir pricing model

published date
November 12th, 2020 by

Steve scaled e1603726353244
Dr. Steve Pearson

Drug pricing is the hottest topic in healthcare, and ICER founder Dr. Steve Pearson is the coolest person to discuss it with.

In this episode of the HealthBiz podcast, Steve describes how the Institute for Clinical and Economic Review (ICER) compiles and analyzes clinical evidence to estimate the fair value of treatments for cancer and other serious illnesses. ICER has been especially active during the pandemic, developing a pricing model for remdesivir and other COVID-19 therapies that’s being used in the United States and by health technology assessment agencies around the world.

For fun, he has been reading Paradise Lost by John Milton.

This is the second episode I’ve recorded on COVID-19 drug pricing. Check out the first one: Remdesivir powers activate! with Dr. Surya Singh.

The HealthBiz podcast is now on SpotifyApple PodcastsGoogle Podcasts and  many more services, making it easy to subscribe.

Below is a rough (AI-generated) transcript of the episode.



—–

By healthcare business consultant David E. Williams, president of Health Business Group

 

Data will eat public health: Podcast with Shahir Kassam-Adams

published date
September 24th, 2020 by

The HealthBiz podcast is now on Spotify and will soon be on many more services making it easy to subscribe.

shahir photo
Shahir Kassam-Adams

Shahir Kassam-Adams is one of the most knowledgeable and outspoken people in healthcare. In this episode, Shahir shares his initially unsettling but ultimately reassuring view that “data will eat public health.” He opines on interoperability and explains how his company, Datavant has promoted data sharing on COVID-19, leading to a plethora of interesting and potentially useful projects, including one that models the tradeoffs for specific American cities to reopen.

Check out the links:

—–

By healthcare business consultant David E. Williams, president of Health Business Group

Russia rushes its COVID-19 vaccine. Why all is not what it seems

published date
August 10th, 2020 by
honor guard 67636 1280
Any volunteers?

Russia –yes the Russia that exerts special influence on our president– has done a poor job of keeping the COVID-19 virus in check. But now they claim to have a safe and effective vaccine that’s ready to go.

I’m quoted in the International Business Times (Questions Surround Russia’s Ability to Deliver a Safe, Effective Coronavirus Vaccine)

Some suggest that the vaccine may not be safe – or effective.

“It’s obvious that the Russians are rushing the vaccine to market without adequate testing,” David Eugene Williams, president at Health Business Group, told International Business Times in an email. “It’s possible that the vaccine will work, but there hasn’t been enough time to verify that it’s both safe and effective. The Russians haven’t released any data that would support their claims.”

“I don’t think people will travel to Russia to receive the vaccine because, 1) they won’t trust that it will work, 2) they could get COVID-19 on their travels to Russia, and 3) the Russians may allocate it to their own citizens,” he said.

It would be great if the Russian vaccine works. But we’ll have to wait and see –which is something the developers haven’t done.


By healthcare business consultant David E. Williams, president of Health Business Group.